Iktos is a French startup and pioneer in the application of artificial intelligence to drug discovery. The company develops an integrated platform combining generative AI, retrosynthesis, and robotics to accelerate small-molecule drug discovery from design to preclinical candidate, aiming to reduce timelines to under 24 months.
Tip: The CEO isn't always your best path in. Data Surfer finds the champions and influencers who actually drive purchasing decisions.
| Ownership Private Company |
| Funding $16.3M |
Iktos is a drug discovery company that combines generative AI, retrosynthesis, and robotics to accelerate small-molecule drug design and reduce preclinical candidate timelines.
Iktos operates an integrated platform that combines generative AI, automated synthesis (Iktos Robotics), and biological testing to accelerate drug discovery for the pharmaceutical industry.
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Connect with iktos